Can PSA testing become appropriate public health policy?
作者信息
Albertsen Peter
机构信息
Surgery/Urology, UConn Health, Farmington, Connecticut, USA.
出版信息
BMJ Oncol. 2023 Aug 21;2(1):e000168. doi: 10.1136/bmjonc-2023-000168. eCollection 2023.
Abstract
摘要
相似文献
1
Can PSA testing become appropriate public health policy?
BMJ Oncol. 2023 Aug 21;2(1):e000168. doi: 10.1136/bmjonc-2023-000168. eCollection 2023.
2
PSA testing for men at average risk of prostate cancer.
Public Health Res Pract. 2017 Jul 26;27(3):2731721. doi: 10.17061/phrp2731721.
3
Decision fatigue in low-value prostate cancer screening.
Cancer. 2021 Sep 15;127(18):3343-3353. doi: 10.1002/cncr.33644. Epub 2021 May 27.
4
Improving the Specificity of PSA Screening with Serum and Urine Markers.
Curr Urol Rep. 2018 Aug 13;19(10):80. doi: 10.1007/s11934-018-0828-6.
5
Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge.
BJU Int. 2024 Jan;133(1):104-111. doi: 10.1111/bju.16211. Epub 2023 Nov 2.
6
Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.
BMJ Open. 2014 Dec 24;4(12):e005691. doi: 10.1136/bmjopen-2014-005691.
7
Optimization of PSA screening policies: a comparison of the patient and societal perspectives.
Med Decis Making. 2012 Mar-Apr;32(2):337-49. doi: 10.1177/0272989X11416513. Epub 2011 Sep 20.
8
Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?
Acta Oncol. 2005;44(3):255-64. doi: 10.1080/02841860410002815.
9
Prostate-specific antigen screening: pro.
Curr Opin Urol. 2010 May;20(3):185-8. doi: 10.1097/MOU.0b013e3283384047.
10
Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening.
BMC Cancer. 2011 Apr 21;11:148. doi: 10.1186/1471-2407-11-148.
本文引用的文献
1
Re: Prevalence of MRI Lesions in Men Responding to a GP-led Invitation for a Prostate Health Check: A Prospective Cohort Study.
Eur Urol. 2024 Apr;85(4):395. doi: 10.1016/j.eururo.2023.11.009. Epub 2023 Nov 25.
2
Designing and Implementing a Population-based Organised Prostate Cancer Testing Programme.
Eur Urol Focus. 2022 Nov;8(6):1568-1574. doi: 10.1016/j.euf.2022.06.008. Epub 2022 Jul 8.
3
Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
Eur Urol. 2021 Dec;80(6):703-711. doi: 10.1016/j.eururo.2021.07.024. Epub 2021 Aug 15.
4
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
JAMA. 2018 Mar 6;319(9):883-895. doi: 10.1001/jama.2018.0154.
5
A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
Eur J Epidemiol. 2017 Jun;32(6):521-527. doi: 10.1007/s10654-017-0292-5. Epub 2017 Jul 31.
6
Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial.
Eur Urol. 2013 Dec;64(6):873-5. doi: 10.1016/j.eururo.2013.05.022. Epub 2013 May 14.
7
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
N Engl J Med. 1991 Apr 25;324(17):1156-61. doi: 10.1056/NEJM199104253241702.
Zotero 插件